The next questions in chronic myeloid leukaemia and their answers

David Marin; Antonia Rotolo; Dragana Milojkovic; John Goldman

doi:10.1097/MOH.0b013e32835dd922

The next questions in chronic myeloid leukaemia and their answers

David Marin, Antonia Rotolo, Dragana Milojkovic, John Goldman

Stem Cell Transplantation

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Purpose of Review: In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML). Recent Findings: In recent years, the management of CML patients has increased in complexity as molecular monitoring has brought to the clinical scene new therapeutic targets and the second-generation tyrosine kinase inhibitors have been licensed for first-line use. Summary: In this article, we will try to answer some of the questions that a practising physician may face in clinical practice, such as: What should be the aim of therapy? What is the best front-line therapy? Which patients should receive an allogeneic stem cell transplant?

Original language	English (US)
Pages (from-to)	163-168
Number of pages	6
Journal	Current opinion in hematology
Volume	20
Issue number	2
DOIs	https://doi.org/10.1097/MOH.0b013e32835dd922
State	Published - Mar 2013

Keywords

chronic myeloid leukaemia
dasatinib
imatinib
nilotinib
response
therapy

ASJC Scopus subject areas

Hematology

Access to Document

10.1097/MOH.0b013e32835dd922

Cite this

@article{8c703a25210140b7ad9cacc1fd8e72dd,

title = "The next questions in chronic myeloid leukaemia and their answers",

abstract = "Purpose of Review: In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML). Recent Findings: In recent years, the management of CML patients has increased in complexity as molecular monitoring has brought to the clinical scene new therapeutic targets and the second-generation tyrosine kinase inhibitors have been licensed for first-line use. Summary: In this article, we will try to answer some of the questions that a practising physician may face in clinical practice, such as: What should be the aim of therapy? What is the best front-line therapy? Which patients should receive an allogeneic stem cell transplant?",

keywords = "chronic myeloid leukaemia, dasatinib, imatinib, nilotinib, response, therapy",

author = "David Marin and Antonia Rotolo and Dragana Milojkovic and John Goldman",

year = "2013",

month = mar,

doi = "10.1097/MOH.0b013e32835dd922",

language = "English (US)",

volume = "20",

pages = "163--168",

journal = "Current opinion in hematology",

issn = "1065-6251",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - The next questions in chronic myeloid leukaemia and their answers

AU - Marin, David

AU - Rotolo, Antonia

AU - Milojkovic, Dragana

AU - Goldman, John

PY - 2013/3

Y1 - 2013/3

N2 - Purpose of Review: In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML). Recent Findings: In recent years, the management of CML patients has increased in complexity as molecular monitoring has brought to the clinical scene new therapeutic targets and the second-generation tyrosine kinase inhibitors have been licensed for first-line use. Summary: In this article, we will try to answer some of the questions that a practising physician may face in clinical practice, such as: What should be the aim of therapy? What is the best front-line therapy? Which patients should receive an allogeneic stem cell transplant?

AB - Purpose of Review: In this review, we analyze some of the topical issues in the clinical management of chronic myeloid leukaemia (CML). Recent Findings: In recent years, the management of CML patients has increased in complexity as molecular monitoring has brought to the clinical scene new therapeutic targets and the second-generation tyrosine kinase inhibitors have been licensed for first-line use. Summary: In this article, we will try to answer some of the questions that a practising physician may face in clinical practice, such as: What should be the aim of therapy? What is the best front-line therapy? Which patients should receive an allogeneic stem cell transplant?

KW - chronic myeloid leukaemia

KW - dasatinib

KW - imatinib

KW - nilotinib

KW - response

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84873404573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873404573&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e32835dd922

DO - 10.1097/MOH.0b013e32835dd922

M3 - Review article

C2 - 23334193

AN - SCOPUS:84873404573

SN - 1065-6251

VL - 20

SP - 163

EP - 168

JO - Current opinion in hematology

JF - Current opinion in hematology

IS - 2

ER -

The next questions in chronic myeloid leukaemia and their answers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this